|
|
|
| Updates in prostate cancer detections and treatments - Messages from 2017 EAU and AUA |
| Xie Liping,Li Jiangfeng,Wang Xiao
|
Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China
Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China
Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China |
|
|
|
|
|
|
Received: 01 August 2017
Published: 07 March 2018
|
|
|
| [1] |
S. Carlsson, G.R. Arnsrud, E. Holmberg, H. Lilja, M. M?nsson, J. Stranne , et al. 235-At what age should a PSA-based screening program start? 20-year results from the G?teborg randomized population-based prostate cancer screening study. Eur Urol Suppl, 16(2017), pp. e406-e408
|
| [2] |
S. Urata, Y. Kitagawa, A. Mizokami . Is further screening of Asian men with low baseline prostate-specific antigen levels(≤1.0 ng/ml) worthwhile? Eur Urol Suppl, 16(2017), pp. e411-e413
|
| [3] |
P. Callerot, M.P. Moineau, I. Cussenot, F. Baschet, J. L’ Her, L. Doucet, et al. 239-Prostate cancer screening in high risk families: should PSA testing be performed yearly in first degree relatives with baseline PSA≤1ng/mL? Eur Urol Suppl, 16(2017), pp. e416-e417
|
| [4] |
P. Dell'Oglio, A. Stabile, G. Gandaglia, G. Brembilla, T. Maga, G. Cristel, et al. MP77-15 Inclusion of mpMRI into the European randomized study of screening for prostate cancer (ERSPC) risk calculator: a new proposal to improve the accuracy of prostate cancer detection. J Urol, 197(2017), p. e1027
|
| [5] |
Y. Sun, Y. Huang, L. Xie, L. Zhou, D. He, Q. Ding, et al. Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with Western cohorts.J Urol, 197(2017), pp. 90-96
|
| [6] |
S. Ren, Z. Peng, J.H. Mao, Y. Yu, C. Yin, X. Gao, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res, 22(2012), p. 806
|
| [7] |
L.P. Xie, X. Wang, X.Y. Zheng, B. Liu, J.F. Li, S. Wang . A randomized controlled trial to assess and compare the outcomes of AI-US-CT guided biopsy, transrectal ultrasound guided 12-core systematic biopsy, and mpMRI assisted 12-core systematic biopsy. Eur Urol Suppl, 16(2017), pp. e865-e866
|
| [8] |
M. Ferriero, A. Giacobbe, R. Papalia, D. Collura, E. Altobelli, R. Mastroianni , et al. Diagnostic performance of multiparametric MRI in prostate cancer: per core analysis of three prospective ultrasound/MRI fusion biopsy datasets. Eur Urol Suppl, 16(2017), pp. e1101-e1102
|
| [9] |
B. Calio, A. Sidana, D. Sugano, A. Jain, M. Maruf, M. Merino , et al. MP03-03 Changes in prostate cancer detection rate of fusion vs systematic biopsy overtime: a single center experience. J Urol, 197(2017), pp. e19-20
|
| [10] |
T. Ishikawa, T. Yoneyama, Y. Tobisawa, S. Hatakeyama, T. Kurosawa, K. Nakamura , et al. 347-An automated-microcapillary electrophoresis-based immunoassay system may improve diagnostic accuracy of prostate cancer and be a good indicator of biopsy Gleason score. Eur Urol Suppl, 16(2017), pp. e610-e612
|
| [11] |
T. Steuber, P. Tennstedt, A. Macagno, B. Golding, R. Schiess, S. Gillessen . 617-A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: findings of a recent study. Eur Urol Suppl, 16(2017), pp. e1066-e1067
|
| [12] |
S. Luzzago, N. Suardi , P. Dell'Oglio, N. Fossati, U. Capitanio, G. Gandaglia, et al. MP77-16 First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer. J Urol, 197(2017), pp. e1027-e1028
|
| [13] |
A. Retter, F. Giganti, A. Kirkham, C. Allen, S. Punwani, M. Emberton , et al. 803-MRI as a follow up tool in active surveillance-results from an MRI-defined active surveillance cohort (387 men, median 5-year follow-up). Eur Urol Suppl, 16(2017), pp. e1398-e1399
|
| [14] |
M. Van Kuiken, R.H. Blackwell, B. Bisanz, J. Yacoub, A. Goldberg, S. Shea , et al. PD55-09 Role of mpMRI PSA density and PIRADS score in predicting upstaging in men on active surveillance. J Urol, 197(2017), p. e1054
|
| [15] |
F. Porpiglia, C. Fiori, R. Bertolo, M. Manfredi, F. Mele, D. Garrou , et al. PD18-06 5 years follow-up of a prospective randomised controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy: oncological and functional outcomes. J Urol, 197(2017), p. e361
|
| [16] |
P. Chang, A. Wagner, M. Regan, D. Patil, C. Crociani, L. Hembroff , et al. PD18-08 Prospective multicenter comparison of open and robotic radical prostatectomy: the PROST-QA/RP2 consortium. J Urol, 197(2017), p. e362
|
| [17] |
G. Auffenberg, R. Dunn, T. Kim, J. Peabody, M. Menon, D. Miller . PD18-02. Measuring to improve: patient reported outcomes during the first year after prostatectomy in a statewide collaborative. J Urol, 197(2017), pp. e359-e360
|
| [18] |
S. Morizane, S. Fukasawa, A. Komaru, J. Inokuchi, M. Eto, M. Shimbo , et al. 929-Comparison of the limited and extended lymphadenectomy during robot-assisted radical prostatectomy for prostate cancer: does the extended lymphadenectomy affect the complications?. Eur Urol Suppl, 16(2017), pp. e1620-e1621
|
| [19] |
P. Zareba, J. Eastham, P. Scardino, K. Touijer . 812-Combined androgen deprivation and radiation versus either modality alone or observation after radical prostatectomy in patients with pathologic node-positive prostate cancer: analysis of a national hospital cancer registry database. Eur Urol Suppl, 16(2017), p. e1416
|
| [20] |
K. Richards , J.i. Liou, V. Cryns, T. Downs, J. Abel, D. Jarrard.MP53-08 Metformin use is associated with improved survival in veterans with advanced prostate cancer on androgen deprivation therapy. J Urol, 197(2017), pp. e715-e716
|
| [21] |
A. Komiya, Y. Yoshioka, T. Kotsuma, M. Kariya, K. Konishi, N. Nonomura , et al. 814-Nationwide multicenter retrospective study on high-dose-rate brachytherapy as monotherapy for prostate cancer. Eur Urol Suppl, 16(2017), p. e1418
|
| [22] |
S. Siva, C. Udovich, M. Shaw, J. Violet, S. Chander, M. Bressel , et al. 962-Stereotactic radiotherapy for bone and nodal oligometastases: patterns of relapse in a prospective clinical trial. Eur Urol Suppl, 16(2017), pp. e1674-e1676
|
| [23] |
N. Fossati, R.J. Karnes, S. Boorjian, M. Colicchia, A. Bossi, T. Seisen , et al. PD72-03 Timing of salvage radiation therapy and use of concomitant hormonal therapy for patients with PSA rising after radical prostatectomy: long-term survival analysis. J Urol, 197(2017), p. e1362
|
| [24] |
K. Hagiwara, S. Hatakeyama, Y. Tobisawa, T. Yoneyama, A. Imai, T. Yoneyama , et al. 1062-Cost effectiveness comparison between neoadjuvant chemo-hormonal therapy and extended lymph node dissection in patients with high-risk prostate cancer. Eur Urol Suppl, 16(2017), pp. e1846-e1847
|
| [25] |
L. Tosco, S. Joniau, M. Witters, A. Battaglia, L. Cromphout, K. Goffin , et al. 957-Predictive factors of positive 68 Ga-PSMA PET/CT in patients with PSA recurrence following radical prostatectomy. Eur Urol Suppl, 16(2017), pp. e1667-e1669
|
| [26] |
F. Saad, D. Heinrich, S. Gillessen , J. O'Sullivan, J. Carles, M. Wirth, et al. 57-Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP). Eur Urol Suppl, 16(2017), pp. e93-e94
|
| [27] |
I. Heidegger, T. Kohl, D. Pfister, H. Friederike, P. Paffenholz, A. Heidenreich . 58-The importance of imaging studies to monitor treatment with novel AR-targeted agents in metastatic castration resistant prostate cancer (mCRPC). Eur Urol Suppl, 16(2017), p. e95
|
| [28] |
A. Borkowetz, M. Toma, S. Füssel, K. Erdmann, P. Hoenscheid, M. Froehner , et al. 491-Expression of neuropilin 2 as predictor for tumour-related death in patients with prostate cancer. Eur Urol Suppl, 16(2017), p. e848
|
| [29] |
R. Na, S.L. Zheng, M. Han, H. Yu, D. Jiang, S. Shah , et al. 481-Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol Suppl, 16(2017), pp. e832-e833
|
| [30] |
C. Salter, J. Cullen, I. Rosner, H.C. Kuo, A. Metwalli . MP14-18 Alkaline phosphatase velocity predicts metastasis among prostate cancer patients who experience biochemical recurrence after radical prostatectomy. J Urol, 197(2017), pp. e168-e169
|
| [31] |
R. Alam, J.J. Tosoian, Y.A. Nyame, L. Wilkins, K. Yousefi, M.R. Chappidi , et al. PD07-08 A novel nomogram to predict postoperative biochemical recurrence in patients with localized high-risk prostate cancer. J Urol, 197(2017), pp. e130-e131
|
| [32] |
B. Xu, C. Luo, Q. Zhang, J. Jin . Preoperative characteristics of the P.R.O.S.T.A.T.E. scores: a novel predictive tool for the risk of positive surgical margin after radical prostatectomy. Eur Urol Suppl, 16(2016), pp. e1843-e1845
|
| No related articles found! |
|
|
|
|
